SCNI Company Profile and Key Details

Scinai Immunotherapeutics Ltd. has 999.92 thousand shares outstanding. The public float is 2.44 billion shares, elevated short interest at 27.67% of float. This equals 275.35 thousand shares. The short ratio is 0.1 days. Institutional investors hold 5.0% of the float. Insiders own 14.16%.

Scinai Immunotherapeutics Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.78. This means the shares are trading above this model’s fair value.

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) closed at $2.34 USD, gaining $0.68 (40.96%) from the previous close of $1.66. The stock is currently mid-range between its 52-week high and low $1.60 and $16.40. With a market capitalization of about $1.21 million, Scinai Immunotherapeutics Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.08). Key stats such as the average daily volume over the past year has been around 148.23 thousand shares, trading with heavier-than-usual volume. Headquartered in Jerusalem, JM, Scinai Immunotherapeutics Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Amir Reichman, the company employs approximately 45 people and listed since May 11, 2015. Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions.

SCNI has shown mixed momentum, gaining 11.1% over the past week and -38.21% over the past quarter, though year-to-date performance is up 21.49%. Short-term trend indicators are mixed aligned (SMA20 3.4%, SMA50 4.11%, SMA200 -42.78%). The stock’s 14-day RSI is 52.4 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -85.92% below its high and over 41.92% above its low. Average 10-day trading volume of 730.51 thousand shares is significantly above the 3-month average of 133.59 thousand, indicating heightened recent market interest.

Scinai Immunotherapeutics Ltd. earnings surprise history is a mixed track record. The quarter that ended July 02, 2024, missed forecasts by 545.16%. The prior quarter beat by -293.55%. Over the last six quarters, Apple has recorded several small beats. These include 38609.68% in May 15, 2024.

Scinai Immunotherapeutics Ltd. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.57 and a price-to-book ratio of 8.07 trading at moderately above to book value. The P/FCF stands at -0.11, also above market averages.

Our AI price prediction model suggests that Scinai Immunotherapeutics Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.04%, with price expected at $1.51 by September 25, 2026, within a range of $1.12 to $1.90 3-Month Outlook: Projected fall of -53.61%, reaching $0.77 by December 10, 2026, with a range of $0.27 to $1.21. 1-Year Outlook: Projected loss of -83.73%, with price at $0.27 by September 10, 2027, within a range of $0.00 to $1.23.

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) shares are up 21.49% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Scinai Immunotherapeutics Ltd. trading at a premium to the broader market with a P/E of -0.0. Our AI forecast model points to short-term weakness (-9.04% over two weeks), a medium-term fall (-53.61% over three months), and a longer-term loss (-83.73% over one year), with expected trading ranges indicating moderate volatility.